Patients with triple-negative breast cancer were regarded as the case group, while patients with hormone receptor-positive and HER2-negative breast cancer and those with any hormone receptor status and HER2-positive breast cancer served as the control group. Here, NR4A1 is linked to triple-negative breast carcinoma.